

# Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review

Christine Herbst,<sup>1</sup> Fareed A. Rehan,<sup>1</sup> Corinne Brilliant,<sup>1</sup> Julia Bohlius,<sup>2</sup> Nicole Skoetz,<sup>1</sup> Holger Schulz,<sup>1</sup> Ina Monsef,<sup>1</sup> Lena Specht,<sup>3</sup> and Andreas Engert<sup>1</sup>

<sup>1</sup>Department I of Internal Medicine, Cochrane Haematological Malignancies Group (CHMG), University Hospital Cologne, Germany; <sup>2</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, and <sup>3</sup>Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Citation: Herbst C, Rehan FA, Brilliant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, and Engert A. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. *Haematologica*. 2010.95:494-500. doi:10.3324/haematol.2009.015644

Online Supplementary Table S1. Characteristics of trials included only in sensitivity analyses.

Trial	Patients	Time of randomization	Treatments	Subgroup of early stage patients reported?	Median length of observation (years)	Overall survival	Tumor control
Laskar 2004 <sup>35</sup>	All stages, age <70 years	In CR	6 x ABVD vs. 6 x ABVD + (mainly) IF-RT	yes; stage I-II: CT: 44 CT+RT: 55	8	CT: 98% CT+RT: 100%	CT: 94% CT+RT: 97%
Nachman 2002 <sup>34</sup>	Children with any stage of HL	In CR	For early stages: 4x COPP/ABV vs. 4x COPP/ABV + low dose IF-RT	yes; stage I-II: CT: 173 CT+RT: 189	3	100% in both groups	CT: 91%± 2.8 (SE) CT+RT: 97% ±1.7 (SE)
O'Dwyer 1984 <sup>47</sup>	Stages IB to IIIA	Before treatment	MOPP vs. MOPP +RT	no CT: 17 CT+RT: 16	6	CT: 2 patients died CT+RT: 3 patients died	CT: 4 patients relapsed CT+RT: 3 patients relapsed
Picardi 2007 <sup>36</sup>	Bulky HL with residual masses in CT that were PET negative at restaging after CT	In CR	6x VEBEP vs. 6x VEBEP + RT	yes; CT: 52 CT+RT: 53	5	100% in both groups	# of patients who relapsed: CT: 6/52 CT+RT: 0/53

*Trials where the number of cycles of chemotherapy varies between trial arms.*

Kung 2006 <sup>38</sup>	Children, PS I-IIIa	In CR or PR	6x MOPP/ABVD vs. 4x MOPP/ABVD + IF-RT	no (31% IIIA)	8	CT: 93.6%±3.9% CT+RT: 96.8%±2.7% P=0.79	CT: 82.6%±5.9% CT+RT: 91.1%± 4.5% P=0.15
Meyer 2005 <sup>20</sup>	Early stage (I-IIA); absence of bulky disease	Before treatment	4-6 x ABVD vs. 2 x ABVD + SN-RT	only early stage	5	HR =1.76 (0.62, 4.68)	HR=0.33 (0.14, 0.80)

NR: not reported; ABVD: adriamycin, bleomycin, vinblastine, dacarbazine; COPP: cyclophosphamide, vincristine, procarbazine and prednisolone; MOPP: mechlorethamine, vincristine, procarbazine, prednisone; VEBEP: etoposide, epirubicin, bleomycin, cyclophosphamide, prednisone; RT: radiotherapy; IF-RT: involved-field radiotherapy; SN-RT: subtotal-nodal radiotherapy; CT: chemotherapy; OS: overall survival.